CRISPR technology is making testing for COVID easier.
FREMONT, CA: Sherlock Biosciences and binx health have partnered with each other to develop the world's premier point-of-care diagnostic test for COVID-19 by leveraging CRISPR technology.
The collaborated organizations will integrate the potential of binx io, which is a diagnostic platform operating on SHERLOCK's CRISPR technology in order to produce the result at high speeds. The test that is designed by the partnership of the two companies delivers results to a patient on a single visit across many CLIA-waived settings, which include clinics, private workplaces of the doctors, life science centers, pharmacies, and other venues that the consumers can easily access.
The binx io is the newest molecular platform that has bagged the recognition of having an FDA clearance certificate. The platform is tested for its expertise in testing for diseases such as chlamydia and gonorrhea. The binx io features a proprietary detection method that has the ability to detect infectious diseases and unfavorable components shot by the fluids in the body.
The innovative platform is more like an instrument of a size of the desktop and a cartridge that can be used just once. The device is also accompanied by multiplex capacity up to 24 targets. The working of the device is easy to understand, as well. Soon after a patient's sample is collected and added to the cartridge, the apparatus is as a whole load into the instrument. The process is a fully automated one, and it will produce a result that is digital in format; it either says "detected" or "not detected" on the screen.
Sherlock Biosciences is one of the leading life sciences companies that was founded on with the vision to improve human health and industrial testing all across the world.
The company is known for its products and services that can be trusted to the highest level. With increased precision and reliability, the diagnostic tests developed with the help of Sherlock's engineering biology platforms are sure to deliver results faster and at affordable prices.